Collecting blood and urine samples from glioblastoma patients receiving radiation therapy
Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence
This study is collecting blood and urine samples from glioblastoma patients receiving radiation therapy to see if certain markers can help predict if their cancer will come back.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Drugs / interventions | radiation |
| Locations | 1 site (Bethesda, Maryland) |
| Trial ID | NCT00083512 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect blood and urine samples from patients with glioblastoma multiforme who are undergoing radiation therapy. The focus is on analyzing the effects of radiation on blood cells and specific proteins, particularly VEGF and MMPs, which may be linked to cancer recurrence. By examining these samples before, during, and after treatment, researchers hope to identify biomarkers that could predict tumor recurrence and improve treatment strategies. The study will involve patients aged 18 and older who meet specific eligibility criteria.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with histologically confirmed glioblastoma multiforme who are eligible for radiation therapy.
Not a fit: Patients with other cancers or those who have undergone specific treatments like Gliadel wafer placement may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the development of new tests for predicting tumor recurrence in glioblastoma patients, potentially improving treatment outcomes.
How similar studies have performed: Preliminary data from earlier studies suggest that measuring urinary VEGF and MMP levels may predict tumor recurrence, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: Age greater than or equal to 18 years. Histologically confirmed supratentorial Glioblastoma multiforme. Karnofsky performance \>60. Patient must be a candidate for radiotherapy. Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA: Patients with other cancers excluding non-melanomatous skin cancers or carcinoma in situ. Gliadel wafer placement at the time of surgery. Pregnancy because radiation has the potential for teratogenic or abortifacient effects. \<TAB\>\<TAB\>
Where this trial is running
Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Kevin A Camphausen, M.D. — National Cancer Institute (NCI)
- Study coordinator: Theresa C Cooley Zgela, R.N.
- Email: theresa.cooleyzgela@nih.gov
- Phone: (301) 451-8905
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.